Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases

Pancreatic Cancer Clinical Trial

Official title:

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Road II, Shanghai 200025, China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05193162
• Other study ID #: (2021)Clin. Ethics Appr. (257)
• Status: Recruiting
• Start date: February 1, 2019
• Est. completion date: July 31, 2026

Study information

• Verified date: June 2023
• Source: Ruijin Hospital
• Contact: Wei Wang, Dr.
• Phone: +86- 13761648121
• Email: wangwei_0306[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The great harm of pancreatic diseases and the unknown etiology and pathogenesis make it difficult to intervene in most early cases in time. Previous studies by scholars and applicants at home and abroad have shown that the microflora in pancreatic tissue is closely related to chronic pancreatitis and pancreatic cancer. However, the research on the mechanism of microbial diversity in pancreatic tissue and the occurrence and development of various pancreatic diseases has not been reported. Based on the previous research, this subject continues to take various pancreatic diseases as the research object based on the database of pancreatic center and pathology department of Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, To explore the characteristics of microbial flora in pancreas in different pancreatic diseases and its mechanism of influence on disease microenvironment. Select specific microbial flora or targets in the pancreas for various pancreatic diseases, so as to provide new theoretical basis and practical guidance for the early diagnosis and treatment of pancreatic diseases.

Description:

AIMS:

To explore the correlation between the characteristics of microbial flora in pancreas and clinical and pathological characteristics of patients with various pancreatic diseases; To clarify the similarities and differences of microbial flora in pancreas in different pancreatic diseases; Select the specific microbial flora or targets in the pancreas for various pancreatic diseases; To provide a new theoretical basis and practical guidance for the early diagnosis, treatment and prognosis of pancreatic diseases.

METHODS:

（1）Patients with various pancreatic diseases operated from January 2005 to June 2022, including but not limited to: pancreatic ductal adenocarcinoma, chronic pancreatitis, pancreatic serous cystadenoma, pancreatic mucinous cystadenoma, intraductal papillary mucinous tumor, pancreatic neuroendocrine tumor, pancreatic acinar cell carcinoma, solid pseudopapillary tumor of pancreas and other pancreatic diseases.

(2) According to the database of Ruijin Hospital, about 30 age and sex matched cases were selected for each pancreatic disease.

(3) All the participants provided written informed consent for participating in the study. If the patient dies, there is an ethical exemption. The collecting procedures have no intervention or impact on treatment measures.

(4)The lesion tissue and adjacent pancreatic tissue were obtained from the paraffin tissue made from the surgical specimens for sampling.

(5)High throughput sequencing was performed according to the instructions of 16S rRNA gene sequencing kit or macro gene detection kit. Anosim (analysis of similarities) statistical method was used for similarity analysis to analyze the correlation between microbiota differences and patients' clinical characteristics (including but not limited to various clinical symptoms, serological indexes, tumor stage, prognosis, and human whole exon sequencing, etc.), pathological type and grade, whether to transfer or not.

(6)According to the instructions of immunohistochemical detection and immunofluorescence detection, the relative abundance and localization of microorganisms in different pancreatic tissues of different pancreatic diseases in different cells (tumor cells, immune cells, normal pancreatic acinar cells, duct cells, etc.) were detected.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 800
• Est. completion date: July 31, 2026
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 85 Years

Eligibility

Inclusion Criteria:

• Age = 5 years old, = 85 years old;

• After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases;

• No history of antibiotics for three months before surgery, no history of yogurt containing probiotics

• There is no serious damage to heart, liver and kidney function.

Exclusion Criteria:

• Antibiotics or yogurt containing probiotics history in three months;

• Patients with evidence of sensory or motor neuropathy;

• Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection;

• Those who have a history of other cancers.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Microbial Colonization
• Pancreatic Cancer
• Pancreatic Disease
• Pancreatic Diseases
• Pancreatic Neoplasms

Intervention

Other:
• No any intervention
have no any intervention

Locations

Country	Name	City	State
China	Ruijin Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	16sRNA and metagenomics	To obtain intestinal microbial information in patients with pancreatic cancer and other pancreatic diseases, to obtain microbial community structure, evolutionary relationship and information on microbial and environmental correlation in the intestinal environmental samples (weight unit: gram). The patient's microbiological characteristics were correlated with the patient's clinical characteristics and prognosis, so as to obtain the relevant biomarker information.	7/2026